Disagreements between central clinical events committee and site investigator assessments of myocardial infarction endpoints in an international clinical trial: review of the PURSUIT study

Table 5 Clinical events committee event rates (%) at 30 days

	All patients			With reclassification^*
Event	Eptifibatide	Placebo	P	Eptifibatide	Placebo	P
Death or myocardial infarction
Eastern Europe	21.0	19.7		18.0	17.9
Latin America	16.1	15.7		14.1	13.2
North America	11.7	15.0		11.7	15.0
Western Europe	13.8	14.8		12.9	13.7
Overall	14.2	15.7	0.042	13.3	14.9	0.021
Myocardial infarction
Eastern Europe	18.8	17.3		15.8	15.3
Latin America	11.6	11.7		9.6	9.1
North America	10.1	12.9		10.1	12.9
Western Europe	12.6	12.9		11.7	11.8
Overall	12.6	13.6	0.137	11.6	12.7	0.08

^*See Methods; 98 patients with low clinical certainty reclassified as having no infarction.

ISSN: 1745-6215